3,295 Matching Annotations
  1. Feb 2024
  2. Jan 2024
  3. Sep 2023
  4. Jul 2023
    1. no we don't
      • Answer

        • No.
        • we end up with a non conceptual insight that:
          • we can then communicate
          • that we can discuss
          • that we can articulate
          • that requires that reason be present at:
            • the beginning like the seed
            • in the middle when we're performing the analysis
            • like the rain that nourishes the crops and
            • in the end in the harvest
          • because non conceptuality is really easy to achieve all you need is a very large rock,
            • just bang right on your head and non conceptuality is there
          • but that's a mute inert non-conceptual
          • Non-conceptuality needs to be enriched by the conceptual insight that allows you to actually make something of it
      • The Middle Way

        • using the conceptual to reach a deeper appreciation of the state of non-conceptuality,
        • in other words, using dualistic thought and language to reach insights about the nondual
  5. Mar 2023
  6. Feb 2023
    1. Moran said the codes themselves may end up limiting the reach of misinformation. As they get more cryptic, they become harder to understand. If people are baffled by a unicorn emoji in a post about COVID-19, they might miss or dismiss the misinformation.
  7. Jan 2023
    1. For a while, I forgot how fun it is to talk to users People seem to intuitively help you if you build something useful for them. And they come up with better ideas than you do.

      Peter Hagen, 2022-08-24 https://twitter.com/peterhagen_/status/1562535573134254080

      One can dramatically increase their potential combinatorial creativity not only by having their own ideas run into each other, for example in a commonplace book or card index/zettelkasten, but by putting them out into the world and allowing them to very actively interact with other people and their ideas.

      Reach, engagement and other factors may also help in the acceleration, but keep in mind that you also need to have the time and bandwidth to listen and often build context with those replies to be able to extract the ultimate real value out of those interactions.

  8. Dec 2022
    1. Alas, lawmakers are way behind the curve on this, demanding new "online safety" rules that require firms to break E2E and block third-party de-enshittification tools: https://www.openrightsgroup.org/blog/online-safety-made-dangerous/ The online free speech debate is stupid because it has all the wrong focuses: Focusing on improving algorithms, not whether you can even get a feed of things you asked to see; Focusing on whether unsolicited messages are delivered, not whether solicited messages reach their readers; Focusing on algorithmic transparency, not whether you can opt out of the behavioral tracking that produces training data for algorithms; Focusing on whether platforms are policing their users well enough, not whether we can leave a platform without losing our important social, professional and personal ties; Focusing on whether the limits on our speech violate the First Amendment, rather than whether they are unfair: https://doctorow.medium.com/yes-its-censorship-2026c9edc0fd

      This list is particularly good.


      Proper regulation of end to end services would encourage the creation of filtering and other tools which would tend to benefit users rather than benefit the rent seeking of the corporations which own the pipes.

    2. That same enshittification is on every platform, and "freedom of speech is not freedom of reach" is just a way of saying, "Now that you're stuck here, we're going to enshittify your experience."
  9. May 2022
    1. “It was 2017, I would say, when Twitter started really cracking down on bots in a way that they hadn’t before — taking down a lot of bad bots, but also taking down a lot of good bots too. There was an appeals process [but] it was very laborious, and it just became very difficult to maintain stuff. And then they also changed all their API’s, which are the programmatic interface for how a bot talks to Twitter. So they changed those without really any warning, and everything broke.

      Just like chilling action by political actors, social media corporations can use changes in policy and APIs to stifle and chill speech online.

      This doesn't mean that there aren't bad actors building bots to actively cause harm, but there is a class of potentially helpful and useful bots (tools) that can make a social space better or more interesting.

      How does one regulate this sort of speech? Perhaps the answer is simply not to algorithmically amplify these bots and their speech over that of humans.

      More and more I think that the answer is to make online social interactions more like in person interactions. Too much social media is giving an even bigger bullhorn to the crazy preacher on the corner of Main Street who was shouting at the crowds that simply ignored them. Social media has made it easier for us to shout them back down, and in doing so, we're only making them heard by more. We need a negative feedback mechanism to dampen these effects the same way they would have happened online.

    1. We've had three things happen simultaneously: we've moved from an open web where people start lots of small projects to one where it really feels like if you're not on a Facebook or a YouTube, you're not going to reach a billion users, and at that point, why is it worth doing this? Second, we've developed a financial model of surveillance capitalism, where the default model for all of these tools is we're going to collect as much information as we can about you and monetize your attention. Then we've developed a model for financing these, which is venture capital, where we basically say it is your job to grow as quickly as possible, to get to the point where you have a near monopoly on a space and you can charge monopoly rents. Get rid of two aspects of that equation and things are quite different.

      How We Got Here: Concentration of Reach, Surveillance Capitalism, and Venture Capital

      These three things combined drove the internet's trajectory. Without these three components, we wouldn't have seen the concentration of private social spaces and the problems that came with them.

  10. Nov 2021
    1. -Fludarabine phosphate may be rapidly dephosphorylated by Phosphorylase cleavage to 2-fluoro-arabinosyladenine and then phosphorylated intracellularly by Deoxycytidine Kinase to the active triphosphate, 2-fluoro-arabinosyl-ATP.

      DCK catalyzes the conversion of phosphate into triphosphoric acid.

    2. Calicheamicin (ozogamicin) is released from the antibody inside the lysosomes of cells.

      calicheamicin translocates to the lysosome.

    3. The abundance of nucleoside transporters on a tumor or host cell may be a major determinant of the amount of nucleoside or nucleoside analog that is taken up into a particular tissue type.

      nucleoside translocates to the host cell.

    4. -Fludarabine phosphate may be rapidly dephosphorylated by Phosphorylase cleavage to 2-fluoro-arabinosyladenine and then phosphorylated intracellularly by Deoxycytidine Kinase to the active triphosphate, 2-fluoro-arabinosyl-ATP.

      DCK phosphorylates triphosphoric acid.

    5. The combined use with fludarabine may lead to severe, even fatal, pulmonary toxicity.Fludarabine phosphate ([(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid, 2-fluoro-ara-AMP) <Fludara, Oforta> is a fluorinated analog of vidarabine.Fludarabine phosphate is susceptible to glycosidic bond cleavage, which results in the formation of 2-fluoro-adenine, and is further converted to the highly toxic 2-fluoro-ATP.Fludarabine phosphate may be rapidly dephosphorylated by Phosphorylase cleavage to 2-fluoro-arabinosyladenine and then phosphorylated intracellularly by Deoxycytidine Kinase to the active triphosphate, 2-fluoro-arabinosyl-ATP.

      DCK phosphorylates triphosphoric acid.

    6. Similar in action to cytarabine, fazarabine is phosphorylated by Deoxycytidine Kinase to a triphosphate form, which competes with thymidine for incorporation into the DNA.

      DCK phosphorylates triphosphoric acid.

    7. -Fludarabine phosphate may be rapidly dephosphorylated by Phosphorylase cleavage to 2-fluoro-arabinosyladenine and then phosphorylated intracellularly by Deoxycytidine Kinase to the active triphosphate, 2-fluoro-arabinosyl-ATP.

      DCK phosphorylates phosphate.

    8. -This agent inhibits serine/threonine Protein Phosphatase type 2A (and to a lesser extent type 1) and Protein Phosphatase 4 (PP4), which leads to phosphorylation and reorganization of Vimentin filaments, thereby interfering with cellular proliferation.

      Phosphatase leads to the phosphorylation of VIM.

    9. At higher concentrations and longer exposure times, the slightly lipophilic agent clofarabine also enters cells by passive diffusion across lipid membranes.Clofarabine is phosphorylated by cytosolic kinases, including Deoxycytidine Kinase (DCK) and a Purine Nucleoside Monophosphate Kinase, to yield the active form clofarabine triphosphate.

      clofarabine phosphorylates DCK.

    10. At higher concentrations and longer exposure times, the slightly lipophilic agent clofarabine also enters cells by passive diffusion across lipid membranes.Clofarabine is phosphorylated by cytosolic kinases, including Deoxycytidine Kinase (DCK) and a Purine Nucleoside Monophosphate Kinase, to yield the active form clofarabine triphosphate.
    11. The poly-glutamylation of anti-folates has been attempted to stabilize the compounds.Thymidylate Synthase inhibitors Thymidylate Synthase catalyzes the methylation of 2′-deoxyuridine-5′-monophosphate (dUMP) to 2′-deoxythymidine-5′monophosphate (dTMP), which is subsequently phosphorylated to thymidine triphosphate, an essential precursor in DNA synthesis (Fig. 2.42 ).

      dTMP phosphorylates dTTP.

    12. The poly-glutamylation of anti-folates has been attempted to stabilize the compounds.Thymidylate Synthase catalyzes the methylation of 2′-deoxyuridine-5′-monophosphate (dUMP) to 2′-deoxythymidine-5′-monophosphate (dTMP), which is subsequently phosphorylated to thymidine triphosphate, an essential precursor in DNA synthesis (Fig. 2.42).

      dTMP phosphorylates dTTP.

    13. This may reflect altered condensation with pyrophosphorylribose-5-phosphate (PRPP) or activation via the salvage pathway that involves ribose-1-phosphate or deoxyribose-1-phosphate and the appropriate Nucleoside Phosphorylase, with subsequent phosphorylation of the resultant nucleoside by Uridine Kinase or Thymidine Kinase.

      uridine phosphorylates nucleoside.

    14. 6-Mercaptopurine is inactivated via two major pathways,thiol methylation is catalyzed by the highly polymorphic enzyme Thiopurine S-Methyltransferase (TPMT), to form methyl-6-mercaptopurine.oxidation is catalyzed by Xanthine Oxidase and forms 6-thiouric acid.The metabolic products are rapidly eliminated by the kidneys, with close to 50 % of the administered dose being excreted in the first 24 h.Bone marrow depression is the main toxic effect.

      Thiopurine S-Methyltransferase (TPMT) leads to the methylation of thiol.

    15. blocked, comprising the synthesis of tetrahydrofolate ( THF), 1-carbon donors (1 C donors), and the production of essential molecules for cell proliferation regulatory elements are associated with clinical outcome in the treatment of osteosarcoma or childhood acute lymphoblastic leukemia (ALL).
    16. blocked, comprising the synthesis of tetrahydrofolate ( THF), 1-carbon donors (1 C donors), and the production of essential molecules for cell proliferation regulatory elements are associated with clinical outcome in the treatment of osteosarcoma or childhood acute lymphoblastic leukemia (ALL).
    17. Ototoxicity (tinnitus and hearing loss) can lead to deafness.
    18. Triaziquone produces myelosclerotic reactions with low frequency.P53 is a critical tumor suppressor protein that may arrest cell cycle progression or induce apoptosis.
    19. Adverse Effects Triaziquone produces myelosclerotic reactions with low frequency.P53 is a critical tumor suppressor protein that may arrest cell cycle progression or induce apoptosis.
    20. Ototoxicity (tinnitus and hearing loss) can lead to deafness.

      Tinnitus inhibits Deafness.

    21. In an inactivation step, Carbonyl Reductase (AKR1B10) catalyzes the reduction of daunorubicin to the alcohol daunorubicinol.
    22. In an inactivation step, Carbonyl Reductase (AKR1B10) catalyzes the reduction of daunorubicin to the alcohol daunorubicinol.The clinical use of anthracycline antibiotics is hampered by toxicity in healthy tissues.

      AKR1B10 inhibits ethanol.

    23. Doxifluridine (5′-deoxy-5-fluorouridine) is a fluoropyrimidine derivative and oral prodrug of 5-fluorouracil, designed to circumvent the rapid degradation of 5-fluorouracil by Dihydropyrimidine Dehydrogenase in the gut wall and liver.

      DPYD inhibits 5-fluorouracil.

    24. Liposomal daunorubicin is under investigation for the treatment of AIDSrelated Kaposi sarcoma, acute myeloblastic leukemia, multiple myeloma, non-Hodgkin lymphoma, and breast cancer.Pharmacokinetics Carbonyl Reductase (CBR) catalyzes the reduction of daunorubicin to its corresponding alcohol, daunorubicinol, which changes the pharmacological properties of this cancer chemotherapeutic drug.

      CBR1 inhibits ethanol.

    25. The mean terminal elimination half-life of the active metabolite SN-38 is 10–20 h. SN-38 is inactivated via glucuronidation by UGT1A1 (Uridine Diphosphate Glucoronosyltransferase 1A1) into the non-toxic SN-38-glucuronide (SN-38G) and is excreted into the gastrointestinal tract.The most substantial adverse effects of irinotecan are grade 2 or higher nausea and vomiting, alopecia, asthenia, fever, and abdominal pain.

      UGT1A1 inhibits SN-38.

    26. The mean terminal elimination half-life of the active metabolite SN-38 is 10-20 h. SN-38 is inactivated via glucuronidation by UGT1A1 (Uridine Diphosphate Glucoronosyltransferase 1A1) into the non-toxic SN-38-glucuronide (SN-38G) and is excreted into the gastrointestinal tract.Adverse Effects The most substantial adverse effects of irinotecan are grade 2 or higher nausea and vomiting, alopecia, asthenia, fever, and abdominal pain.

      UGT1A1 inhibits SN-38.

    27. Bleomycin is inactivated by the cytosolic Aminohydrolase (Bleomycin Hydrolase).

      BLMH inhibits bleomycin.

    28. blocked, comprising the synthesis of tetrahydrofolate ( THF), 1-carbon donors (1 C donors), and the production of essential molecules for cell proliferation regulatory elements are associated with clinical outcome in the treatment of osteosarcoma or childhood acute lymphoblastic leukemia (ALL).
    29. blocked, comprising the synthesis of tetrahydrofolate ( THF), 1-carbon donors (1 C donors), and the production of essential molecules for cell proliferation regulatory elements are associated with clinical outcome in the treatment of osteosarcoma or childhood acute lymphoblastic leukemia (ALL).

      BCR inhibits oxolane.

    30. It inhibits Topoisomerase 2, thereby blocking DNA reduplication and RNA synthesis.Razoxane (ICRF 159, ICI 59118) <Razoxin> is a bisdioxopiperazine and a derivative of the chelating agent EDTA.

      TOP inhibits REG1A.

    31. The drug is an intercalator and a Topoisomerase 2 inhibitor that prevents DNA reduplication and ultimately inhibits protein synthesis.

      TOP inhibits translation.

    32. They share a polycyclic aromatic core structure.The 2 main modes of anthracycline action comprise Topoisomerase inhibition and generation of reactive oxygen species.Because first generation anthracyclines are associated with myocardial dysfunction and alopecia, second generation drugs attempt to reduce these adverse effects.Because of enhanced total body clearance, epirubicin can be used at high cumulative doses without increased cardiotoxicity.Oligosaccharide anthracyclines induce hematopoietic differentiation.The diaminoalkyl groups are crucial for the biological activity of anthracenediones.

      TOP inhibits dioxygen.

    33. Platelet counts may drop.Drug Resistance Treatment with verapamil may reduce resistance to tallimustine.MEN 10710 is a synthetic distamycin derivative that possesses four methyl-pyrrole rings and a bis-(2-chloroethyl) aminophenyl moiety linked to the oligopyrrole backbone by a flexible butanamido chain.Brostallicin (PNU-166196) is a bromo-acrylamido tetrapyrrole distamycin derivative with high cytotoxic potency.
    34. Methotrexate ((S)-2-(4-(((2,4-diaminopteridin-6-yl) methyl)methylamino)benzamido) pentanedioic acid, mtx, amethopterin, MTX) <Trexall> binds to, and competitively and reversibly inhibits the enzyme Dihydrofolate Reductase.
    35. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.
    36. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Other pyrimidine antagonists Penclomedine (3,5-dichloro -2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.
    37. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Other pyrimidine antagonists Penclomedine (3,5-dichloro -2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.
    38. Dietary folates must be chemically reduced to their tetrahydro-forms, bearing four hydrogens on the pteridine ring, to be active.

      folates inhibits pteridine.

    39. In the presence of folates, fluorodeoxyuridine monophosphate binds tightly to and interferes with the function of Thymidylate Synthase, resulting in decreased thymidine synthesis and consecutively reduced DNA synthesis.
    40. The parent compound also releases a thiophilic carbamoylating methyl isocyanate, which inhibits the DNA repair enzyme O6-Alkyl-Guanine Transferase.
    41. The parent compound also releases a thiophilic carbamoylating methyl isocyanate, which inhibits the DNA repair enzyme O 6 -Alkyl-Guanine Transferase.
    42. Among the transcription factors down-regulated by olivomycin A is c-MYC, a major regulator of DNA synthesis and cell survival.The drug effect is not dependent on P53, which implies efficacy in cancers with loss of function in P53.Chromomycin A3 (toyomycin, aburamycin) is a fermentation product of Streptomyces griseus.
    43. Among the transcription factors downregulated by olivomycin A is c-MYC, a major regulator of DNA synthesis and cell survival.Drug Resistance The drug effect is not dependent on P53, which implies efficacy in cancers with loss of function in P53.Chromomycin A3 (toyomycin, aburamycin) is a fermentation product of Streptomyces griseus.
    44. Mitoxantrone hydrochloride (DHAD, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl) amino]ethyl]amino]-9,10-anthracenedione dihydrochloride) (NSC-29919) <Novantrone> intercalates into and cross-links DNA, thereby disrupting DNA reduplication and RNA synthesis.
    45. Razoxane inhibits Topoisomerase 2 without inducing DNA strand breaks, thereby inhibiting DNA synthesis and inducing cytotoxicity.

      razoxane inhibits TOP.

    46. Also shaded in pink are the nitrogen substitutions of the base in fazarabine and decitabine blocks thymidylate synthesis.
    47. The agent is lipophilic.Metoprine (DDMP, 2,4-diamino-5-(3′,4′-dichlorophenyl)-6-methylpyrimidine) (BW 197U) is a diaminopyrimidine folate antagonist that inhibits Dihydrofolate Reductase, resulting in decreased cellular folate metabolism and cell growth.

      antagonist inhibits DHFR.

    48. Drug Resistance The clinical use of anthracycline antibiotics is hampered by the development of resistance in tumor cells, which may be due to an over-expression of ABCB1 (MDR1, PGP), increased levels of enzymes that protect form reactive oxygen damage, activation of the transcription factor NF-κB that exerts crucial functions in cellular resistance to oxidants, altered topoisomerase 2 gene expression or activity, or enzymatic drug inactivation.The anthracycline daunorubicin was originally isolated from bacteria in soil samples taken from the Italian castle Castel del Monte.

      anthracycline inhibits drug.

    49. Because aminosalicylate derivatives may inhibit the enzyme Thiopurine S-Methyltransferase (TPMT) they should be administered with caution to patients on 6-mercaptopurine therapy.The mercaptopurine derivative methylthioinosine (6-(methylmercapto)purine riboside, 6-MMPR) inhibits Amidophosphoribosyl Transferase, the first committed step in de novo purine synthesis, and inhibits cell proliferation induced by Fibroblast Growth Factor-2 (FGF-2).
    50. Because aminosalicylate derivatives may inhibit the enzyme Thiopurine S-Methyltransferase (TPMT) they should be administered with caution to patients on 6-mercaptopurine therapy.The mercaptopurine derivative methylthioinosine (6-(methylmercapto)purine riboside, 6-MMPR) inhibits Amidophosphoribosyl Transferase, the first committed step in de novo purine synthesis, and inhibits cell proliferation induced by Fibroblast Growth Factor-2 (FGF-2).
    51. Cyclophosphamide treatment, which causes a marked and persistent inhibition of Cholinesterase activity, potentiates the effect of succinylcholine chloride.
    52. The compound of arabinose and cytosine is metabolized by Deoxycytidine Kinase and other nucleotide kinases to a nucleotide triphosphate, which is an effective inhibitor of DNA Polymerase A and competes with thymidine for incorporation into DNA.
    53. The compound of arabinose and cytosine is metabolized by Deoxycytidine Kinase and other nucleotide kinases to a nucleotide triphosphate, which is an effective inhibitor of DNA Polymerase A and competes with Fig. 2.46 Pathways of 5-fluorouracil metabolism.
    54. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.Clofarabine triphosphate inhibits Ribonucleotide Reductase, leading to a depletion of the deoxyribonucleotide triphosphate (dNTP) pools.Clofarabine induces apoptosis through direct and indirect action on mitochondria by releasing Cytochrome c and other pro-apoptotic factors, including AIF (Apoptosis Inducing Factor), APAF-1 (Apoptotic Protease Activating Factor-1), and Caspase-9.The agent received accelerated approval from the U.S. FDA in 2004.
    55. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.Clofarabine triphosphate inhibits Ribonucleotide Reductase, leading to a depletion of the deoxyribonucleotide triphosphate (dNTP) pools.Clofarabine induces apoptosis through direct and indirect action on mitochondria by releasing Cytochrome c and other pro-apoptotic factors, including AIF (Apoptosis Inducing Factor), APAF-1 (Apoptotic Protease Activating Factor-1), and Caspase-9.The agent received accelerated approval from the U.S. FDA in 2004.
    56. The agent is activated to its triphosphate inside the tumor cells.-Clofarabine acts by terminating DNA chain elongation and inhibiting DNA repair through incorporation into the DNA.
    57. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.
    58. Because of the bone marrow suppression, vaccinations during or shortly before or shortly after chemotherapy with mechlorethamine should be avoided.Drug Interactions Turmeric may decrease the effect of mechlorethamine.
    59. Cimetidine is an inhibitor of microsomal drug metabolism that may increase the half-life and toxicity of hexamethylmelamine.Water soluble analogs of hexamethylmelamine have been produced because of gastrointestinal adverse effects associated with the oral administration of the water insoluble preparation.
    60. Tegafur competes with uridine triphosphate, thus inhibiting RNA and protein synthesis.

      Tegafur inhibits translation.

    61. Because of this sequence selectivity, mithramycin A blocks the binding of the SP-1 family of transcription factors to C/G-rich sequences in gene promoters and inhibits gene transcription, which in turn alters the regulation of cell proliferation and differentiation.
    62. These carboplatin induced DNA and protein effects result in apoptosis and cell growth inhibition.
    63. These carboplatin induced DNA and protein effects result in apoptosis and cell growth inhibition.
    64. Methyl benzyl hydrazine derivatives can suppress mitosis by prolonging interphase.ThioTEPA ( N, N′,N′-triethylenethiophosphoramide) <Thio-plex> was first developed by American Cyanamid in the early 1950s.
    65. Hence the drug efficacy can potentially be enhanced by Helicase inhibitors.Illudins and acylfulvenes alkylate DNA, inhibit DNA synthesis, and deplete thiol anti-oxidant defenses.In 1965, cisplatin was discovered by Barnett Rosenberg, who explored the effects of electric fields on the growth of Escherichia coli bacteria (Rosenberg 1965) .

      cisplatin inhibits thiol.

    66. The inhibition of Adenosine Deaminase by deoxycoformycin leads to an intracellular accumulation of deoxy-ATP, which causes apoptosis.

      deoxycoformycin inhibits ADA.

    67. Camptothecin also inhibits RNA synthesis.Irinotecan is an S phase specific agent.Camptothecins exist in a pH dependent equilibrium between their active lactone and inactive ring-opened conformations.The stability of the lactone ring at physiological pH is a determinant of activity for all camptothecin analogs.Topotecan and irinotecan are substrates for the efflux pump ABCB1.

      camptothecin inhibits S phase.

    68. Camptothecin also blocks RNA synthesis through Topoisomerase 1 mediated effects.Because camptothecin exists in equilibrium between the lactone and the ring-opened conformations its drug action is limited.
    69. Camptothecin also blocks RNA synthesis through Topoisomerase 1 mediated effects.Pharmacokinetics Because camptothecin exists in equilibrium between the lactone and the ring-opened conformations its drug action is limited.
    70. Mitomycin C at high concentrations also inhibits RNA and protein synthesis.
    71. The coupling to a styrene maleic acid based polymer reduces the immunogenicity of neocarzinostatin.

      styrene inhibits Zinostatin.

    72. Triaziquone produces myelosclerotic reactions with low frequency.P53 is a critical tumor suppressor protein that may arrest cell cycle progression or induce apoptosis.
    73. Thus, the effects of inosine dialdehyde are different from those caused by typical inhibitors of Ribonucleotide Reductase, which rapidly suppress DNA synthesis and cause arrest of the cells in G1, with minimal effects on RNA and protein synthesis.In salvage pathways, nucleotides are synthesized from intermediates of canonical degradative pathways.
    74. Thus, the effects of inosine dialdehyde are different from those caused by typical inhibitors of Ribonucleotide Reductase, which rapidly suppress DNA synthesis and cause arrest of the cells in G 1 , with minimal effects on RNA and protein synthesis.In salvage pathways, nucleotides are synthesized from intermediates of canonical degradative pathways.
    75. This metabolite inhibits DNA Polymerase α, Ribonucleotide Reductase, and DNA Primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.Fludarabine is used in the treatment of hematologic malignancies.

      metabolite inhibits repB.

    76. It is given at 50-70 mg/ m 2 by intravenous bolus every 3-4 weeks.Adverse Effects The limiting toxicity of lobaplatin is thrombocytopenia, with a nadir at approximately 2 weeks after drug administration.
    77. Nausea, vomiting, diarrhea, and an elevation of hepatic enzymes and bilirubin occur less often.Trimetrexate glucuronate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline mono-D-glucuronate) <Neutrexin> is a lipid soluble methotrexate derivative that inhibits Dihydrofolate Reductase.

      glucuronate inhibits DHFR.

    78. Unlike methotrexate, edatrexate has additive activity when used with cisplatin.Talotrexin ammonium (N(α )-(4-amino-4-deoxypteroyl)- N(δ)-hemiphthaloyl-L-ornithine) (PT523) <Talvesta> is a non-polyglutamable anti-metabolite analog of aminopterin that binds to and inhibits the function of Dihydrofolate Reductase.
    79. 6-Mercaptopurine can inhibit the anti-coagulant effect of warfarin, when given simultaneously.
    80. In cancer cells that lack functional P53, DZQ mediated p21 induction is greatly diminished.
    81. The coupling to a styrene maleic acid based polymer reduces the immunogenicity of neocarzinostatin.
    82. Its cytotoxicity is not affected by disruption of P53 function or loss of DNA repair.In the presence of divalent cations, aureolic acid antibiotics form dimers that non-intercalatively bind to the DNA minor groove in high-GC-content regions.Upon binding to DNA, the aureolic acid chromophores form hydrogen bonds with NH2 residues of guanines.Mithramycin A binds to C/G-rich tracts as a dimer and blocks SP-1 family transcription factors.Ecteinascidin-743 effects guanine N2 alkylation.After intravenous administration, mitomycin C is rapidly cleared from the blood with a half-life of about 15 min.
    83. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Other pyrimidine antagonists Penclomedine (3,5-dichloro -2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.
    84. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Penclomedine (3,5-dichloro-2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and cross-links DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.
    85. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Other pyrimidine antagonists Penclomedine (3,5-dichloro -2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.
    86. Because of its higher concentration in the combination, uracil saturates the uracil reducing enzymatic activity of Ddihydropyrimidine Ddehydrogenase, thereby inhibiting first pass hepatic metabolism of 5-fluorouracil and permitting its administration as the orally bioavailable prodrug tetrahydrofuranyl-5-fluorouracil.
    87. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Other pyrimidine antagonists Penclomedine (3,5-dichloro -2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.
    88. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.

      dATP inhibits DNA repair.

    89. It acts at an essential step along the de novo path of pyrimidine biosynthesis by inhibiting Orotidylate Decarboxylase, which suppresses the formation of uridylic acid from its carboxylated precursor, orotidylic acid.
    90. FUMP is further metabolized to FUTP, which inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand, thereby suppressing cell growth.

      UTP inhibits cell growth.

    91. The therapeutic index of bis(sulfonyl)hydrazine compounds may therefore be more favorable.Methyl benzyl hydrazine derivatives can suppress mitosis by prolonging interphase.

      hydrazine inhibits interphase.

    92. -Methyl benzyl hydrazine derivatives can suppress mitosis by prolonging interphase.

      hydrazine inhibits interphase.

    93. Their activation occurs with the release of the single-bonded nitrogen, leaving the highly reactive double-bonded diazonium fragment exposed.Oral availability and penetration of the blood-brain barrier vary among triazenes.The bis(sulfonyl)hydrazines are alkylating agents that produce chloroethylating species.Methyl benzyl hydrazine derivatives can suppress mitosis by prolonging interphase.Because absorption from the gastrointestinal tract is variable, thioTEPA should not be administered orally.
    94. The therapeutic index of bis(sulfonyl)hydrazine compounds may therefore be more favorable.Methyl benzyl hydrazine derivatives can suppress mitosis by prolonging interphase.
    95. Methyl benzyl hydrazine derivatives can suppress mitosis by prolonging interphase.ThioTEPA ( N, N′,N′-triethylenethiophosphoramide) <Thio-plex> was first developed by American Cyanamid in the early 1950s.
    96. -Methyl benzyl hydrazine derivatives can suppress mitosis by prolonging interphase.
    97. Also shaded in pink are the nitrogen substitutions of the base in fazarabine and decitabine blocks thymidylate synthesis.
    98. Edatrexate inhibits Thymidylate Synthase and Glycinamide Ribonucleotide Formyl Transferase, impairing the synthesis of purine nucleotides and amino acids, and resulting in tumor cell death.
    99. Edatrexate inhibits Thymidylate Synthase and Glycinamide Ribonucleotide Formyl Transferase, impairing the synthesis of purine nucleotides and amino acids, and resulting in tumor cell death.

      edatrexate inhibits TYMS.

    100. Edatrexate inhibits Thymidylate Synthase and Glycinamide Ribonucleotide Formyl Transferase, impairing the synthesis of purine nucleotides and amino acids, and resulting in tumor cell death.

      edatrexate inhibits Formyl Transferase.

    101. It is associated with the production of the neurotoxic metabolite chloroacetaldehyde.Dose fractionation and hydration aid substantially in limiting the toxicities of ifosfamide.

      Aid inhibits ifosfamide.

    102. Hence the drug efficacy can potentially be enhanced by Helicase inhibitors.Illudins and acylfulvenes alkylate DNA, inhibit DNA synthesis, and deplete thiol anti-oxidant defenses.In 1965, cisplatin was discovered by Barnett Rosenberg, who explored the effects of electric fields on the growth of Escherichia coli bacteria (Rosenberg 1965) .

      Helicase inhibits drug.

    103. Liposomal PEGylated forms of daunorubicin have been designed to increase the amount of drug delivered to tumors and decrease the peak distribution to the heart and gastrointestinal mucosa.

      daunorubicin increases the amount of drug.

    104. 3,6-diaziridinyl-1,4benzoquinone (DZQ) causes the increased expression of P21 CIP1/WAF1 , an inhibitor of Cyclin-Dependent Kinases.

      benzoquinone increases the amount of CDKN1A.

    105. 3,6-diaziridinyl-1,4-benzoquinone (DZQ) causes the increased expression of P21CIP1/WAF1, an inhibitor of Cyclin-Dependent Kinases.
    106. -Fludarabine phosphate may be rapidly dephosphorylated by Phosphorylase cleavage to 2-fluoro-arabinosyladenine and then phosphorylated intracellularly by Deoxycytidine Kinase to the active triphosphate, 2-fluoro-arabinosyl-ATP.
    107. -Fludarabine phosphate may be rapidly dephosphorylated by Phosphorylase cleavage to 2-fluoro-arabinosyladenine and then phosphorylated intracellularly by Deoxycytidine Kinase to the active triphosphate, 2-fluoro-arabinosyl-ATP.

      Phosphorylases dephosphorylates phosphate.

    108. After uptake, it is O-demethylated by Adenosine Deaminase to ara-G, mono-phosphorylated by Deoxyguanosine Kinase and Deoxycytidine Kinase, and subsequently converted to the biologically active 9-β-D-arabinosylguanine 5′-triphosphate (ara-GTP).

      ADA demethylates araG.

    109. It displays an acceptable safety profile.Sensitive tumor cells convert the prodrug 6-mercaptopurine to thioinosinate and 6-methylthioinosinate, which inhibit Glutamine-5-Phosphoribosylpyrophosphate Amidotransferase, the first enzyme unique to the de novo synthesis pathway for purine ribonucleotides.The Adenosine Deaminase (ADA) inhibitor co-vidarabine is effective against several lymphoproliferative conditions, but not acute lymphocytic leukemia because the transformed cells contain too high levels of Adenosine Deaminase.After uptake, nelarabine is O-demethylated by Adenosine Deaminase to ara-G, mono-phosphorylated by Deoxyguanosine Kinase and Deoxycytidine Kinase, and subsequently converted to the biologically active 9-β-D-arabinosylguanine 5′-triphosphate (ara-GTP).

      ADA demethylates araG.

    110. Non-steroidal anti-inflammatory drugs (NSAIDs) and probenecid reduce the tubular secretion of methotrexate.

      probenecid decreases the amount of methotrexate.

    111. Forodesine binds preferentially to and inhibits Purine Nucleotide Phosphorylase, resulting in the accumulation of deoxyguanosine triphosphate, the subsequent inhibition of the enzyme Ribonucleoside Diphosphate Reductase49, and the abrogation of DNA synthesis.
    112. Phenylbutazone, sodium salicylate, and aspirin can displace Albumin bound etoposide.

      etoposide binds ALB.

    113. Estramustine and its major metabolite bind covalently to microtubule-associated proteins (MAPs) and Tubulin, thereby causing their separation from the microtubules, inhibiting microtubule assembly, and eventually causing their disassembly.Estramustine is taken orally, at least 1 h before or 2 h after meals.
    114. Functional groups that differ from the parent compound, daunorubicin, are highlighted in pink cline and HCHO then react to form a conjugate, in which two anthracycline molecules bind together with three methylene groups, two forming oxazolidine rings and one binding the oxazolidines together at their 3′-amino nitrogens.
    115. Due to the affinity of PtII for sulfur binding, platinum drugs can bind to Glutathione, Metallothionein, and serum Albumin.

      platinum binds ALB.

    116. Due to the affinity of PtII for sulfur binding, platinum drugs can bind to Glutathione, Metallothionein, and serum Albumin.
    117. The mechanism of action involves the drug binding to CD33 antigen on the AML cell membrane, then being internalized.

      drug binds CD33.

    118. The drug is Pregnancy Category D.Drug Interactions Drug interaction with cimetidine, amphotericin B, digoxin, or phenytoin may arise and require adjust-ment.
    119. It depends on binding of a bleomycin/iron complex to DNA, which then reduces molecular oxygen to free oxygen radicals that cause primarily single strand breaks.Bleomycin sulfate <Blenoxane, Teva> is used in the treatment of Hodgkin and non-Hodgkin lymphoma as a component of the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen, of squamous cell carcinoma, and of testicular cancer.
    120. Due to the affinity of PtII for sulfur binding, platinum drugs can bind to Glutathione, Metallothionein, and serum Albumin.
    121. ABCC2 (ATP-Binding Cassette sub-family C 2, MRP2, cMOAT) also has a role in cisplatin resistance, presumably by promoting drug efflux.

      ATP binds ABCC2.

    122. ABCC2 (ATP-Binding Cassette sub-family C 2, MRP2, cMOAT) also has a role in cisplatin resistance, presumably by promoting drug efflux.increased cytoplasmic detoxification through cellular thiols such as Glutathione (GSH).

      ATP binds ABCC2.

    123. Major binding interactions between the apoprotein and the chromophore are the hydrophobic contacts between the core of the chromophore and the hydrophobic side chains of the pocket forming residues.Neocarzinostatin (zinostatin, vinostatin), discovered in 1964, was the first enediyne antibiotic used clinically and has become a prototypical anti-cancer agent for the treatments of leukemia, gastric carcinoma and pancreatic adenocarcinoma.
    124. Cardiac toxicity may cause tachycardia or left ventricular systolic dysfunction.Nelarabine (506U78) <Arranon, Atriance> is an arabinonucleoside anti-metabolite prodrug.
    125. Triaziquone produces myelosclerotic reactions with low frequency.P53 is a critical tumor suppressor protein that may arrest cell cycle progression or induce apoptosis.
    126. Adverse Effects Triaziquone produces myelosclerotic reactions with low frequency.P53 is a critical tumor suppressor protein that may arrest cell cycle progression or induce apoptosis.
    127. Uracil mustard may rarely cause stomatitis, associated with considerable discomfort.Uracil mustard can raise the concentration of blood uric acid.

      Stomatitis activates uric acid.

    128. Severe pancytopenia can arise and sometimes lead to death.

      Pancytopenia activates Death.

    129. Other adverse effects include mild nausea and vomiting during treatment, bone marrow hypoplasia, nephrosis, emesis, and bloody diarrhea.Prior treatment with a nitrosourea enhances the hematopoietic toxicity of indicine-N-oxide.Dianhydrogalactitol (1,2:5,6-diepoxyhexane-3,4-diol, 1,2-di(oxiranyl)ethylene glycol, dulcitol diepoxide, DAG) (NSC 132313) is a bifunctional hexitol diepoxide that was developed in Budapest (Nemeth et al. 1972).

      Nausea activates hexitol.

    130. Dapsone has been used to treat Kaposi sarcoma.Adverse effects include hemolysis, which may lead to hemolytic anemia, and methemoglobinemia.
    131. Dapsone has been used to treat Kaposi sarcoma.Adverse Effects Adverse effects include hemolysis, which may lead to hemolytic anemia, and methemoglobinemia.
    132. Acidic pH promotes the formation of the lactone, while a more basic pH favors the hydroxy acid anion form.
    133. Dapsone has been used to treat Kaposi sarcoma.Adverse effects include hemolysis, which may lead to hemolytic anemia, and methemoglobinemia.
    134. Dapsone has been used to treat Kaposi sarcoma.Adverse Effects Adverse effects include hemolysis, which may lead to hemolytic anemia, and methemoglobinemia.
    135. It is secreted in the milk.Irinotecan can induce both early and late forms of diarrhea, which may be severe.Early diarrhea can be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping.

      Diarrhea activates Miosis.

    136. It is secreted in the milk.Irinotecan can induce both early and late forms of diarrhea, which may be severe.Early diarrhea can be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping.

      Diarrhea activates Flushing.

    137. It is secreted in the milk.Irinotecan can induce both early and late forms of diarrhea, which may be severe.Early diarrhea can be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping.
    138. It depends on binding of a bleomycin/iron complex to DNA, which then reduces molecular oxygen to free oxygen radicals that cause primarily single strand breaks.Bleomycin sulfate <Blenoxane, Teva> is used in the treatment of Hodgkin and non-Hodgkin lymphoma as a component of the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen, of squamous cell carcinoma, and of testicular cancer.
    139. However, the polyethylene glycol (PEG) in the formulation may cause hand-foot syndrome as an adverse effect29.Liposomal daunorubicin <DaunoXome> is a liposome encapsulated preparation with a diameter of 45 nm that is free of polyethylene glycol.
    140. glycol (PEG) in the formulation may cause hand-foot syndrome as an adverse effect 29 .
    141. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.Clofarabine triphosphate inhibits Ribonucleotide Reductase, leading to a depletion of the deoxyribonucleotide triphosphate (dNTP) pools.Clofarabine induces apoptosis through direct and indirect action on mitochondria by releasing Cytochrome c and other pro-apoptotic factors, including AIF (Apoptosis Inducing Factor), APAF-1 (Apoptotic Protease Activating Factor-1), and Caspase-9.The agent received accelerated approval from the U.S. FDA in 2004.

      APAF1 activates CYCS.

    142. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.Clofarabine triphosphate inhibits Ribonucleotide Reductase, leading to a depletion of the deoxyribonucleotide triphosphate (dNTP) pools.Clofarabine induces apoptosis through direct and indirect action on mitochondria by releasing Cytochrome c and other pro-apoptotic factors, including AIF (Apoptosis Inducing Factor), APAF-1 (Apoptotic Protease Activating Factor-1), and Caspase-9.The agent received accelerated approval from the U.S. FDA in 2004.
    143. Because aminosalicylate derivatives may inhibit the enzyme Thiopurine S-Methyltransferase (TPMT) they should be administered with caution to patients on 6-mercaptopurine therapy.The mercaptopurine derivative methylthioinosine (6-(methylmercapto)purine riboside, 6-MMPR) inhibits Amidophosphoribosyl Transferase, the first committed step in de novo purine synthesis, and inhibits cell proliferation induced by Fibroblast Growth Factor-2 (FGF-2).
    144. Increases in the catabolism of 5-fluorouracil, mainly dependent on the rate limiting enzyme Dihydropyrimidine Dehydrogenase, can cause resistance to fluoropyrimidine based chemotherapy.

      DPYD activates catabolic process.

    145. thioTEPA is activated by CYP3A4 and CYP2D6.

      CYP3A4 activates Thiotepa.

    146. thioTEPA is activated by CYP3A4 and CYP2D6.

      CYP2D6 activates Thiotepa.

    147. Liposomal daunorubicin is under investigation for the treatment of AIDS-related Kaposi sarcoma, acute myeloblastic leukemia, multiple myeloma, non-Hodgkin lymphoma, and breast cancer.Carbonyl Reductase (CBR) catalyzes the reduction of daunorubicin to its corresponding alcohol, daunorubicinol, which changes the pharmacological properties of this cancer chemotherapeutic drug.

      CBR1 activates ethanol.

    148. The P53 pathway can partially mediate cisplatin cytotoxicity.

      TP53 activates cisplatin.

    149. Drug resistance may be caused by platinum efflux, detoxification through thiols, apoptosis resistance, or enhanced DNA repair.MINOR GROOVE DNA BINDING ANTIBIOTICS (A/T RICH SITES)MINOR GROOVE DNA BINDING ANTIBIOTICS (G/C RICH SITES)) is a methylazirinopyrroloindoledioneFig.
    150. The S phase specific induction of DNA damage responses by adozelesin depends on active reduplication forks.

      S phase activates DNA Damage.

    151. Individuals with this condition may develop life threatening toxicity following exposure to 5-fluorouracil or capecitabine.Reduced anabolism of 5-fluorouracil to the nucleotide form can lead to drug resistance.
    152. However, in cells lacking the tumor suppressor protein P21, bizelesin, as well as adozelesin, trigger apoptosis, reflecting a crucial role for P21 in sustained bizelesin induced G 2 /M arrest (Cao 2003) .
    153. The drug is an intercalator and a Topoisomerase 2 inhibitor that prevents DNA reduplication and ultimately inhibits protein synthesis.

      TOP activates translation.

    154. Whereas both cyclophosphamide and ifosfamide are activated by Cytochromes P450 2B1 and 2C6/2C11, only ifosfamide is also activated by Cytochrome P450 3A.N-dechloroethylation of the parent drug yields mono-functional metabolites that have lost their DNA cross-linking activity and therapeutic efficacy.

      CYP activates ifosfamide.

    155. Whereas both cyclophosphamide and ifosfamide are activated by Cytochromes P450 2B1 and 2C6/2C11, only ifosfamide is also activated by Cytochrome P450 3A.N-dechloroethylation of the parent drug yields mono-functional metabolites that have lost their DNA cross-linking activity and therapeutic efficacy.

      CYP activates ifosfamide.

    156. Whereas both cyclophosphamide and ifosfamide are activated by Cytochromes P450 2B1 and 2C6/2C11, only ifosfamide is also activated by Cytochrome P450 3A.N-dechloroethylation of the parent drug yields mono-functional metabolites that have lost their DNA cross-linking activity and therapeutic efficacy.

      CYP activates cyclophosphamide.

    157. The kinase PKB (Protein Kinase B, AKT) promotes cell survival and down-regulates apoptosis.

      AKT activates Cell Survival.

    158. Allopurinol may be preferred to prevent or reverse uracil mustard induced hyperuricemia and the risk of uric acid nephropathy.Estramustine phosphate sodium (estradiol 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt, monohydrate) <Emcyt> is an orally available synthetic drug that combines estradiol and mechlorethamine through a carbamate link.
    159. Allopurinol may be preferred to prevent or reverse uracil mustard induced hyperuricemia and the risk of uric acid nephropathy.Steroid-coupled nitrogen mustards Estramustine phosphate sodium (estradiol 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt, monohydrate) <Emcyt> is an orally available synthetic drug that combines estradiol and mechlorethamine through a carbamate link.
    160. Uracil mustard may rarely cause stomatitis, associated with considerable discomfort.Drug Interactions Uracil mustard can raise the concentration of blood uric acid.
    161. Uracil mustard may rarely cause stomatitis, associated with considerable discomfort.Uracil mustard can raise the concentration of blood uric acid.
    162. Uracil mustard may rarely cause stomatitis, associated with considerable discomfort.Drug Interactions Uracil mustard can raise the concentration of blood uric acid.
    163. ThioTEPA causes amenorrhea and interferes with spermatogenesis.

      Thiotepa activates Amenorrhea.

    164. Thioguanine causes birth defects if taken during pregnancy.Administration of a live vaccine can be dangerous during treatment with thioguanine.
    165. Thioguanine causes birth defects if taken during pregnancy.
    166. Streptozocin prolongs the elimination half-life of doxorubicin and thus can lead to severe bone marrow suppression.
    167. When combined with ethanol, procarbazine can cause adverse drug reactions in some patients.
    168. Clofarabine can produce systemic inflammatory response syndrome (SIRS) and capillary leak syndrome, manifested by the rapid development of tachypnea, tachycardia, hypotension, shock, and multi-organ failure.
    169. Clofarabine can produce systemic inflammatory response syndrome (SIRS) and capillary leak syndrome, manifested by the rapid development of tachypnea, tachycardia, hypo-47 The ENT transporters work bi-directionally, driven by the nucleoside concentration gradient between the inside and the outside of the cell membrane.
    170. Clofarabine can produce systemic inflammatory response syndrome (SIRS) and capillary leak syndrome, manifested by the rapid development of tachypnea, tachycardia, hypotension, shock, and multi-organ failure.
    171. The agent can be effectively combined with other nucleoside analogs, particularly clofarabine and gemcitabine, which inhibit Ribonucleotide Reductase.Penclomedine (3,5-dichloro-2,4-dimethoxy-6 trichloromethyl pyridine) (NSC338720) is a synthetic derivative of pyrimidine that alkylates and cross-links DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis.

      clofarabine activates pyrimidine.

    172. It has been under investigation as a second-line treatment for various cancers.As an alkylating agent, dimethylbusulfan induces neutropenia.Treosulfan (2,3-dihydroxybutane-1,4-diyl dimethanesulfonate) (NSC 39069) is the prodrug of a bifunctional sulfonate alkylating agent, which converts non-enzymatically via a monoepoxide intermediate to L-diepoxybutane.
    173. It has been under investigation as a second-line treatment for various cancers.Adverse Effects As an alkylating agent, dimethylbusulfan induces neutropenia.Treosulfan (2,3-dihydroxybutane-1,4-diyl dimethanesulfonate) (NSC 39069) is the prodrug of a bifunctional sulfonate alkylating agent, which converts non-enzymatically via a monoepoxide intermediate to L-diepoxybutane.
    174. It has been under investigation as a second-line treatment for various cancers.As an alkylating agent, dimethylbusulfan induces neutropenia.Treosulfan (2,3-dihydroxybutane-1,4-diyl dimethanesulfonate) (NSC 39069) is the prodrug of a bifunctional sulfonate alkylating agent, which converts non-enzymatically via a monoepoxide intermediate to L-diepoxybutane.
    175. It has been under investigation as a second-line treatment for various cancers.Adverse Effects As an alkylating agent, dimethylbusulfan induces neutropenia.Treosulfan (2,3-dihydroxybutane-1,4-diyl dimethanesulfonate) (NSC 39069) is the prodrug of a bifunctional sulfonate alkylating agent, which converts non-enzymatically via a monoepoxide intermediate to L-diepoxybutane.
    176. It has been under investigation as a second-line treatment for various cancers.As an alkylating agent, dimethylbusulfan induces neutropenia.Treosulfan (2,3-dihydroxybutane-1,4-diyl dimethanesulfonate) (NSC 39069) is the prodrug of a bifunctional sulfonate alkylating agent, which converts non-enzymatically via a monoepoxide intermediate to L-diepoxybutane.
    177. It has been under investigation as a second-line treatment for various cancers.Adverse Effects As an alkylating agent, dimethylbusulfan induces neutropenia.Treosulfan (2,3-dihydroxybutane-1,4-diyl dimethanesulfonate) (NSC 39069) is the prodrug of a bifunctional sulfonate alkylating agent, which converts non-enzymatically via a monoepoxide intermediate to L-diepoxybutane.
    178. Inosine dialdehyde (NSC 118994) <Inox> is a toxic purine analog that inhibits Ribonucleotide Reductase, resulting in the decreased synthesis of DNA, RNA, and proteins, and leading to cell cycle arrest at the G2/M transition.
    179. In the presence of folates, fluorodeoxyuridine monophosphate binds tightly to and interferes with the function of Thymidylate Synthase, resulting in decreased thymidine synthesis and consecutively reduced DNA synthesis.
    180. Ifosfamide produces less myelotoxicity (mainly leukopenia) than cyclophosphamide and also exhibits little cross-resistance.

      ifosfamide activates Leukopenia.

    181. The metabolic ifosfamide product acrolein can contribute to the hemorrhagic cystitis associated with oxazaphosphorine therapy.

      ifosfamide activates Cystitis.

    182. Due to its mechanisms of action through genetic damage, etoposide may increase the risk of developing leukemia.

      etoposide activates Leukemia.

    183. O-demethylation of the etoposide dimethoxyphenol ring occurs through the CYP450 3A4 pathway to produce the corresponding catechol.

      etoposide activates catechol.

    184. FdUMP inhibits DNA synthesis and cell division by reducing thymidine production.Several fluorouracil metabolites incorporate into both RNA and DNA.
    185. Hydroxyurea selectively inhibits Ribonucleoside Diphosphate Reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates45.
    186. A ratio of clofarabine triphosphate to dATP < 1 results in the insertion of clofarabine monophosphate into the middle of the DNA structure and inhibits DNA repair.Clofarabine triphosphate inhibits Ribonucleotide Reductase, leading to a depletion of the deoxyribonucleotide triphosphate (dNTP) pools.Clofarabine induces apoptosis through direct and indirect action on mitochondria by releasing Cytochrome c and other pro-apoptotic factors, including AIF (Apoptosis Inducing Factor), APAF-1 (Apoptotic Protease Activating Factor-1), and Caspase-9.The agent received accelerated approval from the U.S. FDA in 2004.
    187. Nausea, vomiting, diarrhea, and an elevation of hepatic enzymes and bilirubin occur less often.Trimetrexate glucuronate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline mono-D-glucuronate) <Neutrexin> is a lipid soluble methotrexate derivative that inhibits Dihydrofolate Reductase.

      methotrexate activates DHFR.